(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Quarter results tomorrow
(bmo 2024-04-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
Šios dienos apimtis | 70 820.00 |
Vidutinė apimtis | 92 922.00 |
Rinkos kapitalizacija | 134.31B |
EPS | €0 ( 2024-01-30 ) |
Kita pelno data | ( €0 ) 2024-04-29 |
Last Dividend | €0.410 ( 2023-07-27 ) |
Next Dividend | €0 ( N/A ) |
P/E | 69.96 |
ATR14 | €0.0470 (0.20%) |
Tūris Koreliacija
Pfizer Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Pfizer Inc Koreliacija - Valiuta/Žaliavos
Pfizer Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €58.50B |
Bruto pelnas: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2023 |
Pajamos: | €58.50B |
Bruto pelnas: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2022 |
Pajamos: | €100.33B |
Bruto pelnas: | €65.99B (65.77 %) |
EPS: | €5.63 |
FY | 2021 |
Pajamos: | €81.29B |
Bruto pelnas: | €50.47B (62.08 %) |
EPS: | €3.95 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.400 (N/A) |
€0.400 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.410 | 2023-07-27 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 68 | -- |
Total Paid Out | €20.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.7 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 4.08 | |
Div. Directional Score | 5.07 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOM.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
2GB.DE | Ex Dividend Junior | 2023-06-14 | Annually | 0 | 0.00% | |
V6C.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
ELG.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
NTH.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
AEIN.DE | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
GOB.DE | Ex Dividend Knight | 2023-06-12 | Sporadic | 0 | 0.00% | |
PSQ.F | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
BLQA.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0367 | 1.500 | 9.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00947 | 1.200 | 9.68 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0222 | 1.500 | -0.864 | -1.296 | [0.1 - 1] |
payoutRatioTTM | 4.31 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.583 | 0.800 | -1.279 | -1.023 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.18 | [0 - 0.6] |
interestCoverageTTM | 0.551 | 1.000 | -0.907 | -0.907 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.796 | -1.500 | 6.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.479 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0208 | 1.000 | -1.584 | -1.584 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.123 | 1.000 | -0.429 | -0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.258 | 0.800 | -1.612 | -1.289 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 66.39 | 1.000 | 3.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0222 | 2.50 | -0.555 | -1.296 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.71 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 4.31 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -2.39 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.149 | 1.000 | 8.78 | 0 | [0.1 - 0.5] |
Total Score | 4.08 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.